Jiang Xuejun, Stockwell Brent R, Conrad Marcus
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Biological Sciences, Columbia University, New York, NY, USA.
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282. doi: 10.1038/s41580-020-00324-8. Epub 2021 Jan 25.
The research field of ferroptosis has seen exponential growth over the past few years, since the term was coined in 2012. This unique modality of cell death, driven by iron-dependent phospholipid peroxidation, is regulated by multiple cellular metabolic pathways, including redox homeostasis, iron handling, mitochondrial activity and metabolism of amino acids, lipids and sugars, in addition to various signalling pathways relevant to disease. Numerous organ injuries and degenerative pathologies are driven by ferroptosis. Intriguingly, therapy-resistant cancer cells, particularly those in the mesenchymal state and prone to metastasis, are exquisitely vulnerable to ferroptosis. As such, pharmacological modulation of ferroptosis, via both its induction and its inhibition, holds great potential for the treatment of drug-resistant cancers, ischaemic organ injuries and other degenerative diseases linked to extensive lipid peroxidation. In this Review, we provide a critical analysis of the current molecular mechanisms and regulatory networks of ferroptosis, the potential physiological functions of ferroptosis in tumour suppression and immune surveillance, and its pathological roles, together with a potential for therapeutic targeting. Importantly, as in all rapidly evolving research areas, challenges exist due to misconceptions and inappropriate experimental methods. This Review also aims to address these issues and to provide practical guidelines for enhancing reproducibility and reliability in studies of ferroptosis. Finally, we discuss important concepts and pressing questions that should be the focus of future ferroptosis research.
自2012年“铁死亡”一词被创造以来,铁死亡的研究领域在过去几年呈指数级增长。这种由铁依赖性磷脂过氧化驱动的独特细胞死亡方式,除了与疾病相关的各种信号通路外,还受多种细胞代谢途径调控,包括氧化还原稳态、铁处理、线粒体活性以及氨基酸、脂质和糖的代谢。许多器官损伤和退行性病变都由铁死亡驱动。有趣的是,对治疗耐药的癌细胞,尤其是那些处于间充质状态且易于转移的癌细胞,对铁死亡极为敏感。因此,通过诱导和抑制铁死亡进行药理学调控,在治疗耐药癌症、缺血性器官损伤以及其他与广泛脂质过氧化相关的退行性疾病方面具有巨大潜力。在本综述中,我们对铁死亡当前的分子机制和调控网络、铁死亡在肿瘤抑制和免疫监视中的潜在生理功能及其病理作用,以及治疗靶点的潜力进行了批判性分析。重要的是,如同所有快速发展的研究领域一样,由于误解和不恰当的实验方法存在挑战。本综述还旨在解决这些问题,并为提高铁死亡研究的可重复性和可靠性提供实用指南。最后,我们讨论了应成为未来铁死亡研究重点的重要概念和紧迫问题。